THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| BRENDAN DEVINE | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JAYMI DOREEN LIGHT New | Staff Assistant, Rep. Todd Young; Legislative Correspondent/Press Assistant, Rep. Todd Young; Legislative Assistant, Rep. Todd Young; Legislative Assistant, U.S. Senator Todd Young; Health Policy Director, U.S. Senator Todd Young |
Defense DEF
* Pharmacy issues related to TRICARE and H.R. 4350 the National Defense Authorization Act (NDAA) for Fiscal Year 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| BRENDAN DEVINE | — |
| GARY J KLINE | — |
Health Issues HCR
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL CANINO KALETA | — |
| CHRISTOPHER DAVIS | — |
| BRENDAN DEVINE | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| JAYMI DOREEN LIGHT New | Staff Assistant, Rep. Todd Young; Legislative Correspondent/Press Assistant, Rep. Todd Young; Legislative Assistant, Rep. Todd Young; Legislative Assistant, U.S. Senator Todd Young; Health Policy Director, U.S. Senator Todd Young |
Affiliated organisations
| Organisation | Location |
|---|---|
| EXPRESS SCRIPTS, INC. | St. Louis, MO, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.